CA2790380A1 - Vaccines for use in the prophylaxis and treatment of influenza virus disease - Google Patents
Vaccines for use in the prophylaxis and treatment of influenza virus disease Download PDFInfo
- Publication number
- CA2790380A1 CA2790380A1 CA2790380A CA2790380A CA2790380A1 CA 2790380 A1 CA2790380 A1 CA 2790380A1 CA 2790380 A CA2790380 A CA 2790380A CA 2790380 A CA2790380 A CA 2790380A CA 2790380 A1 CA2790380 A1 CA 2790380A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- polypeptide
- seq
- hydrophilic
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title claims 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 119
- 229920001184 polypeptide Polymers 0.000 claims abstract 118
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 118
- 206010022000 influenza Diseases 0.000 claims abstract 43
- 239000000203 mixture Substances 0.000 claims abstract 21
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract 4
- 101710176177 Protein A56 Proteins 0.000 claims abstract 4
- 239000000185 hemagglutinin Substances 0.000 claims abstract 4
- 150000001413 amino acids Chemical class 0.000 claims 92
- 230000002209 hydrophobic effect Effects 0.000 claims 34
- 241000700605 Viruses Species 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 230000002163 immunogen Effects 0.000 claims 13
- 230000002378 acidificating effect Effects 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000007999 Nuclear Proteins Human genes 0.000 claims 6
- 108010089610 Nuclear Proteins Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 108010040721 Flagellin Proteins 0.000 claims 3
- 241000607142 Salmonella Species 0.000 claims 3
- 208000037797 influenza A Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30589810P | 2010-02-18 | 2010-02-18 | |
| US61/305,898 | 2010-02-18 | ||
| US12/788,103 US8673314B2 (en) | 2009-05-26 | 2010-05-26 | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US12/788,103 | 2010-05-26 | ||
| US35416010P | 2010-06-11 | 2010-06-11 | |
| US61/354,160 | 2010-06-11 | ||
| US38508310P | 2010-09-21 | 2010-09-21 | |
| US61/385,083 | 2010-09-21 | ||
| PCT/US2011/025467 WO2011103453A2 (en) | 2010-02-18 | 2011-02-18 | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2790380A1 true CA2790380A1 (en) | 2011-08-25 |
Family
ID=44483593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2790380A Abandoned CA2790380A1 (en) | 2010-02-18 | 2011-02-18 | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9701723B2 (OSRAM) |
| EP (1) | EP2536425B1 (OSRAM) |
| JP (3) | JP2013520172A (OSRAM) |
| KR (1) | KR20120132506A (OSRAM) |
| CN (1) | CN102939096B (OSRAM) |
| AU (1) | AU2011217903B2 (OSRAM) |
| BR (1) | BR112012020839A2 (OSRAM) |
| CA (1) | CA2790380A1 (OSRAM) |
| MX (1) | MX342716B (OSRAM) |
| WO (1) | WO2011103453A2 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2413962A1 (en) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| AU2010254136B2 (en) | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| AU2011217903B2 (en) | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| IN2014CN02114A (OSRAM) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| EP4154907A1 (en) | 2012-12-18 | 2023-03-29 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR101768600B1 (ko) * | 2015-05-18 | 2017-08-17 | 한국생명공학연구원 | 범용성 개 인플루엔자 바이러스 백신 조성물 |
| JP6868763B2 (ja) * | 2016-04-01 | 2021-05-12 | パナソニックＩｐマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| US10478488B2 (en) | 2017-10-03 | 2019-11-19 | Southwest Research Institute | Liposomal flu vaccine formulation |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| RU2757013C2 (ru) * | 2017-12-19 | 2021-10-08 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения |
| CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
| CN108329379B (zh) * | 2018-04-08 | 2022-01-28 | 诺华生物科技（武汉）有限责任公司 | H7亚型流感病毒h7n9的普通型/嵌合型病毒样颗粒及制备方法、应用和疫苗 |
| CN108840911B (zh) * | 2018-06-09 | 2021-03-30 | 西北农林科技大学 | 新城疫病毒基质蛋白的抗原表位、抗体、鉴定方法和应用 |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| MX2021000951A (es) | 2018-07-23 | 2021-06-23 | Sumitomo Pharma Co Ltd | Composición que contiene vacuna contra la influenza. |
| CN109097341B (zh) * | 2018-08-28 | 2021-09-24 | 青岛农业大学 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
| CN111363017B (zh) * | 2018-12-25 | 2022-03-15 | 中国科学院微生物研究所 | A型流感病毒核蛋白s69位突变序列及其突变体与应用 |
| EP3936147A4 (en) | 2019-03-04 | 2022-09-28 | JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases | METHOD FOR PREPARING A SPLIT VACCINE AGAINST INFLUENZA HEMAGGLUTININ (HA) |
| TWI857017B (zh) * | 2019-03-04 | 2024-10-01 | 國立感染症研究所長代表之日本國 | 流感ha裂解疫苗之製造方法 |
| CN111134250A (zh) * | 2019-12-03 | 2020-05-12 | 海南大学 | 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法 |
| CN111298098B (zh) * | 2020-02-25 | 2021-10-29 | 中国科学院微生物研究所 | 卡泊芬净在制备抑制冠状病毒的产品中的应用 |
| WO2021188787A1 (en) * | 2020-03-19 | 2021-09-23 | Renibus Therapeutics, Inc. | Method for treatment of coronavirus infection |
| CN117229370B (zh) * | 2022-06-08 | 2024-11-01 | 中科南京生命健康高等研究院 | H5n6禽流感广谱性疫苗的开发及其应用 |
| WO2024097396A1 (en) * | 2022-11-05 | 2024-05-10 | Us Biologic, Inc. | Visco-elastic solid formulation for oral delivery of a biologically active agent |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA836080B (en) * | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US5182192A (en) | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| JP3037554B2 (ja) | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| WO1994016109A1 (en) * | 1993-01-15 | 1994-07-21 | Whitehead Institute For Biomedical Research | Membrane fusion events and means for altering same |
| WO1994017826A1 (en) | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5573916A (en) * | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| MXPA01010921A (es) | 1999-04-29 | 2003-06-24 | Syngenta Ltd | Plantas resistentes a herbicidas. |
| NZ517903A (en) * | 1999-09-24 | 2003-10-31 | Smithkline Beecham Biolog S | One dose intranasal influenza virus vaccine with split influenza viral antigens |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| DE60137345D1 (de) * | 2000-04-28 | 2009-02-26 | St Jude Childrens Res Hospital | Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| HUE050222T2 (hu) | 2002-02-13 | 2020-11-30 | Wisconsin Alumni Res Found | Szignál influenzavírus-vektorok pakolására |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| CA2514177A1 (en) | 2003-01-29 | 2004-08-12 | Josef Michl | Tolerance-induced targeted antibody production |
| ATE426412T1 (de) * | 2003-01-30 | 2009-04-15 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
| JP4368594B2 (ja) | 2003-02-24 | 2009-11-18 | 株式会社インシリコサイエンス | タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体 |
| DE602004028004D1 (de) | 2003-05-05 | 2010-08-19 | Thompson Boyce Plant Res | Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| PL1692265T3 (pl) * | 2003-11-04 | 2011-12-30 | The Administrators Of The Tulane Educational Fund | Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I |
| EP2530147B1 (en) * | 2004-05-25 | 2014-09-10 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| CN101163714A (zh) * | 2005-02-24 | 2008-04-16 | 马萨诸塞大学 | 流感病毒核酸、多肽及其用途 |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| JP4758148B2 (ja) | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
| WO2007052058A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
| WO2007066334A1 (en) * | 2005-12-06 | 2007-06-14 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved influenza vaccine |
| US10183986B2 (en) * | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| CA2657849A1 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| WO2008005777A2 (en) | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| SG173337A1 (en) | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP4585610A3 (en) | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| EP2174957B1 (en) * | 2007-06-15 | 2016-03-16 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| EP2014279A1 (en) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| WO2009025770A2 (en) | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| EP2200639B1 (en) * | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| FR2921387B1 (fr) | 2007-09-26 | 2012-04-20 | Sanofi Pasteur | Procede de production du virus de la grippe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
| RU2010127156A (ru) | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| EP2698380A1 (en) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralizing molecules to viral antigens |
| GB0905570D0 (en) | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
| WO2010003766A2 (en) * | 2008-06-17 | 2010-01-14 | Apogenix Gmbh | Multimeric tnf receptors |
| DK2300609T3 (da) | 2008-06-25 | 2014-02-10 | Inst Nat Sante Rech Med | Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf |
| US8771703B2 (en) | 2008-07-08 | 2014-07-08 | Medicago Inc. | Soluble recombinant influenza antigens |
| EP2413962A1 (en) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| AU2010254136B2 (en) * | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| CA2762042C (en) | 2009-06-24 | 2012-11-20 | Medicago Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
| JP5845180B2 (ja) * | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルス及びそれらの使用 |
| JP5463107B2 (ja) | 2009-09-14 | 2014-04-09 | 独立行政法人国立国際医療研究センター | 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬 |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| AU2011217903B2 (en) | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| EP2545074A4 (en) | 2010-03-08 | 2014-01-08 | Celltrion Inc | HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS |
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| EP2596017B1 (en) | 2010-07-22 | 2019-04-03 | John W. Schrader | Cross-protective antibody against influenza viral infection |
| IN2014CN02114A (OSRAM) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| MY170927A (en) | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| WO2014090865A1 (en) | 2012-12-11 | 2014-06-19 | Vib Vzw | Anti-influenza antibody |
| EP4154907A1 (en) | 2012-12-18 | 2023-03-29 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
-
2011
- 2011-02-18 AU AU2011217903A patent/AU2011217903B2/en not_active Ceased
- 2011-02-18 JP JP2012554060A patent/JP2013520172A/ja not_active Withdrawn
- 2011-02-18 KR KR1020127024205A patent/KR20120132506A/ko not_active Ceased
- 2011-02-18 CA CA2790380A patent/CA2790380A1/en not_active Abandoned
- 2011-02-18 WO PCT/US2011/025467 patent/WO2011103453A2/en not_active Ceased
- 2011-02-18 US US13/579,845 patent/US9701723B2/en active Active
- 2011-02-18 BR BR112012020839A patent/BR112012020839A2/pt not_active Application Discontinuation
- 2011-02-18 MX MX2012009581A patent/MX342716B/es active IP Right Grant
- 2011-02-18 CN CN201180019658.1A patent/CN102939096B/zh not_active Expired - Fee Related
- 2011-02-18 EP EP11745345.6A patent/EP2536425B1/en active Active
-
2016
- 2016-05-24 JP JP2016103689A patent/JP2016196472A/ja not_active Withdrawn
-
2018
- 2018-07-03 JP JP2018126633A patent/JP2018166515A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102939096B (zh) | 2016-03-02 |
| AU2011217903A1 (en) | 2012-09-13 |
| EP2536425A2 (en) | 2012-12-26 |
| EP2536425A4 (en) | 2014-11-05 |
| US9701723B2 (en) | 2017-07-11 |
| JP2018166515A (ja) | 2018-11-01 |
| WO2011103453A2 (en) | 2011-08-25 |
| JP2013520172A (ja) | 2013-06-06 |
| US20130209499A1 (en) | 2013-08-15 |
| US20170114103A9 (en) | 2017-04-27 |
| EP2536425B1 (en) | 2019-06-19 |
| WO2011103453A3 (en) | 2011-12-29 |
| CN102939096A (zh) | 2013-02-20 |
| AU2011217903B2 (en) | 2017-03-02 |
| MX2012009581A (es) | 2013-01-29 |
| JP2016196472A (ja) | 2016-11-24 |
| BR112012020839A2 (pt) | 2017-11-21 |
| MX342716B (es) | 2016-10-11 |
| KR20120132506A (ko) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2790380A1 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| US9592287B2 (en) | Immunopotentiator-linked oligomeric influenza immunogenic compositions | |
| US9889194B2 (en) | Immunogenic composition for MERS coronavirus infection | |
| JP2016196472A5 (OSRAM) | ||
| Yang et al. | A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern | |
| RU2015142996A (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| JP2013520172A5 (OSRAM) | ||
| AU2011331251B2 (en) | Respiratory Syncytial Virus vaccine | |
| JP2012526839A5 (OSRAM) | ||
| JP2013526849A5 (OSRAM) | ||
| JP2012501959A5 (OSRAM) | ||
| WO2007066334A9 (en) | Improved influenza vaccine | |
| JP2017522319A5 (OSRAM) | ||
| RU2015141214A (ru) | Вакцины против Chlamydia sp. | |
| JP2009520758A5 (OSRAM) | ||
| Sączyńska | Influenza virus hemagglutinin as a vaccine antigen produced in bacteria. | |
| JP2019534242A5 (OSRAM) | ||
| JP7407176B2 (ja) | ハウスダストダニアレルギーの処置および予防 | |
| EP2739307B1 (en) | Vlps containing ligands and methods related thereto | |
| WO2011017442A3 (en) | Anti-rsv immunogens and methods of immunization | |
| JP2020536925A5 (OSRAM) | ||
| RU2007129962A (ru) | Универсальная вакцина против вируса гриппа птиц | |
| JP2012501351A5 (OSRAM) | ||
| WO2004062584A3 (en) | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection | |
| CN115850398A (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160212 |
|
| FZDE | Discontinued |
Effective date: 20200831 |
|
| FZDE | Discontinued |
Effective date: 20200831 |